Results 151 to 160 of about 12,381 (205)

PD-1 inhibitor improves radiosensitivity by tumor vessel normalization. [PDF]

Br J Cancer
Hao S, Ai D, Wang Q, Zhang X, Ma X, Tseng I, Shen J, Chen Y, Liu Q, Deng J, Zhu H, Kong Z, Zhao K.   +12 more
europepmc   +1 more source

Comparative In Vitro and In Vivo Evaluation of Anti-CCR8 Full-Sized IgG and Its Fab Fragments in Murine Colorectal Cancer Models. [PDF]

Molecules
Hu T, Jiao R, Allen KJH, Frank C, Malo ME, Dadachova E.   +5 more
europepmc   +1 more source

Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies. [PDF]

J Immunother Cancer
Patel A, Wakeam E, Josephides E, Lampridis S, Karapanagiotou E, Middleton G, Naidu B, De Perrot M, Bille A.   +8 more
europepmc   +1 more source

Genetically engineered Magnesium/Manganese nanoparticles for cancer radioimmunotherapy. [PDF]

J Nanobiotechnology
Wu J, Xu Y, Zhang Y, Zhang K, Zhang J, Guo Y, She P, Rao L, Xu X.   +8 more
europepmc   +1 more source

Engineering baculo- and lentiviral vectors for enhanced and targeted gene delivery (Geeninsiirron tehostaminen ja kohdentaminen pintamuokatuilla bakulo- ja lentiviruksilla) [PDF]

Kaikkonen, Minna
core  

Fingolimod synergizes with anti-PD-1 radioimmunotherapy in an experimental multiple sclerosis model through enhanced lymph node retention and CD8⁺ T cell depletion. [PDF]

Front Med (Lausanne)
Frank C, Allen KJH, Dawicki W, Levin MC, Dadachova E.   +4 more
europepmc   +1 more source

[²²⁵Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer. [PDF]

Breast Cancer Res
Tikum AF, Fon DA, Njotu FN, Henning N, Nwangele E, Babeker H, Ketchemen JP, Doroudi A, Uppalapati M, Fonge H.   +9 more
europepmc   +1 more source

Potential of the "[M(CO)3]+" (M: Re, Tc) Moiety for the Labeling of Biomolecules [PDF]

, 2017
Abram, U., Alberto, R., Egli, A., Knapp, F. F. (Russ), Schibli, R., Schubiger, P. A.   +5 more
core  

A metabolic-radioimmune signature predicts therapy response and immune reprogramming in non-small cell lung cancer. [PDF]

Front Oncol
Zhu Z, Zan Y, Jiang M, Zhang R, Chen D, Dong G.   +5 more
europepmc   +1 more source

Dual Potential of Cetuximab Conjugated Hydroxyapatite Zirconium Nanoparticle as Nanocarrier for Radioenhancer in X-Ray Dynamic Therapy and ¹⁷⁷Lu-based Radioimmunotherapy of Lung Cancer. [PDF]

Nanotheranostics
Kurniawan A, Mahendra I, Rizaludin A, Utama MS, Lesmana R, Ayuningtyas FD, Dewanti MR, Syarif DG, Febrian MB.   +8 more
europepmc   +1 more source